https://openbell.ai/ 2026-10-07T12:46:45.430Z hourly 1.0 https://openbell.ai/support 2026-10-07T12:46:45.430Z monthly 0.7 https://openbell.ai/privacy 2026-10-07T12:46:45.430Z monthly 0.5 https://openbell.ai/terms 2026-10-07T12:46:45.430Z monthly 0.5 https://openbell.ai/feed.json 2026-10-07T12:46:45.430Z hourly 0.8 https://openbell.ai/news/CVX:1791377198974 2026-10-07T12:46:38.974Z daily 0.9 https://cdn.brandfetch.io/CVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chevron Swaps Hess Midstream Stake For 50% Lower Bakken Costs — And A $200 Million Payment Chevron Corporation has entered into agreements with Hess Midstream LP to restructure Bakken midstream contracts, leading to a 50% reduction in unit midstream costs. In exchange for transferring its ownership interests in Hess Midstream and DJ Basin assets, Chevron will receive $200 million in cash and expects to improve its return on capital employed by approximately 0.5 percentage points. However, the company anticipates a one-time after-tax loss of $3 billion to $4 billion at closing. Additionally, Chevron announced senior leadership changes effective January 1, 2027. https://openbell.ai/news/ZS:1791377186943 2026-10-07T12:46:26.943Z daily 0.9 https://cdn.brandfetch.io/ZS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wedbush Maintains Outperform on Zscaler, Raises Price Target to $240 Wedbush analyst Steven Wahrhaftig has maintained an Outperform rating on Zscaler (NASDAQ: ZS) and increased the price target from $215 to $240. This adjustment reflects a positive outlook for the company's performance in the market. https://openbell.ai/news/CIRC:1791377184020 2026-10-07T12:46:24.020Z daily 0.9 https://cdn.brandfetch.io/CIRC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Circle8 Group Announces ~$314M Four-Year Contract Renewal With Dutch Education Agency DUO openbell Financial News https://openbell.ai/news/RCKT:1791377089962 2026-10-07T12:44:49.962Z daily 0.9 https://cdn.brandfetch.io/RCKT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong has reiterated an 'Outperform' rating on Rocket Pharmaceuticals (NASDAQ: RCKT) and maintained a price target of $15 for the stock. This indicates a positive outlook for the company's performance in the market. https://openbell.ai/news/NVDA:1791377079890 2026-10-07T12:44:39.890Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jim Cramer Says Investors Are Overlooking Elon Musk’s $40 Billion ‘Pot of Gold’ For Nvidia — Intel Terafab Exit Rumors ‘Squashed,’ Dismisses ‘Weakness’ In Korea’s Kospi Jim Cramer highlighted a $40 billion investment from Elon Musk to Nvidia Corp. (NASDAQ: NVDA), suggesting that market concerns over the weakness in South Korea's Kospi index are overshadowing this significant capital allocation. Cramer also dismissed rumors of Musk ending his Terafab partnership with Intel Corp. (NASDAQ: INTC), confirming that Intel will continue its involvement in the project. Despite a recent dip in Intel's stock, which fell about 0.91% to $111.48, the shares have increased approximately 202% over the past year. https://openbell.ai/news/KEYS:1791377049661 2026-10-07T12:44:09.661Z daily 0.9 https://cdn.brandfetch.io/KEYS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Top 3 Tech Stocks That May Fall Off A Cliff In Q4 As of October 7, 2026, three tech stocks are identified as potentially overbought: Synopsys Inc (NASDAQ: SNPS), Keysight Technologies Inc (NYSE: KEYS), and NetApp Inc (NASDAQ: NTAP). Synopsys initiated a $1 billion accelerated share repurchase agreement, with shares closing at $505.17, an increase of 3.4%. Keysight's stock rose 1% to $388.03 after a price target increase from Goldman Sachs, while NetApp's shares closed at $228.45, up 2.1%, following a price target increase from TD Cowen. https://openbell.ai/news/GEHC:1791376972134 2026-10-07T12:42:52.134Z daily 0.9 https://cdn.brandfetch.io/GEHC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Initiates Coverage On GE HealthCare Techs with Overweight Rating, Announces Price Target of $85 Barclays analyst Christopher Pasquale has initiated coverage on GE HealthCare Technologies (NASDAQ: GEHC) with an Overweight rating. The firm has set a price target of $85 for the stock. https://openbell.ai/news/AIB:1791376854792 2026-10-07T12:40:54.792Z daily 0.9 https://cdn.brandfetch.io/AIB/w/400/h/400?c=1idopYfmtR7ZKg8QMud AIB Data Centers Issues CEO Letter; Continues To Evaluate Opportunities To Expand Portfolio Of Power-Rich Sites For AI And High-Performance Computing Infrastructure AIB Data Centers has signed a 12-year agreement with Nebius for 50 MW of IT capacity at its CLT1 data center, with two potential five-year renewals. The company completed a strategic acquisition in Texas, increasing its total contracted utility power capacity from 65 MW to approximately 120 MW. AIB plans to fund the development of CLT1 primarily through customer prepayments and project-level financing, without the need for corporate-level common equity. The company continues to evaluate opportunities to expand its portfolio for AI and high-performance computing infrastructure. https://openbell.ai/news/CMND:1791376845382 2026-10-07T12:40:45.382Z daily 0.9 https://cdn.brandfetch.io/CMND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Clearmind Medicine Says It Submitted Recommendations To FDA On Future Therapeutic Use Of Non-Hallucinogenic Psychedelic Drugs openbell Financial News https://openbell.ai/news/OSTX:1791376824479 2026-10-07T12:40:24.479Z daily 0.9 https://cdn.brandfetch.io/OSTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma OS Therapies, Inc. (NYSE: OSTX) announced that its subsidiary OSAH has received guidance from the U.S. Department of Agriculture regarding the commercial development pathway for OST-HER2, aimed at treating canine osteosarcoma. The USDA's feedback pertains to OSAH's upcoming conditional licensure request, focusing on clinical efficacy, safety, and manufacturing controls as part of the pre-commercialization process. https://openbell.ai/news/TDOC:1791376810160 2026-10-07T12:40:10.160Z daily 0.9 https://cdn.brandfetch.io/TDOC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Teladoc Turns Smartphone Cameras Into AI-Powered Vital Sign Monitors Teladoc Health, Inc. (NYSE: TDOC) has introduced two AI-powered tools, SoloVitals and SoloScribe, to enhance its Solo platform for virtual care. SoloVitals enables contactless monitoring of vital signs using smartphone cameras, while SoloScribe automates clinical note-taking during virtual appointments. The Solo platform is currently utilized in over 15,000 care locations globally. Despite a modest premarket stock increase to $5.79, Teladoc's stock has declined 31.06% over the past year and remains below key moving averages. https://openbell.ai/news/EW:1791376808618 2026-10-07T12:40:08.618Z daily 0.9 https://cdn.brandfetch.io/EW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110 Barclays analyst Christopher Pasquale has initiated coverage on Edwards Lifesciences (NYSE: EW) with an Overweight rating. The firm has set a price target of $110 for the stock. https://openbell.ai/news/TDOC:1791376798659 2026-10-07T12:39:58.659Z daily 0.9 https://cdn.brandfetch.io/TDOC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Teladoc Turns Smartphone Cameras Into AI-Powered Vital Sign Monitors Teladoc Health, Inc. (NYSE: TDOC) has introduced two AI-powered tools, SoloVitals and SoloScribe, to enhance its Solo platform, which is currently used in over 15,000 care locations. SoloVitals enables contactless monitoring of heart and respiration rates using smartphone cameras, while SoloScribe automates clinical note-taking during virtual appointments. The stock is trading at $5.79, reflecting a modest increase in premarket trading, although it has fallen 31.06% over the past year and remains below key moving averages. https://openbell.ai/news/NTAP:1791376783189 2026-10-07T12:39:43.189Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/07/Netapp-Sign--Logo-On-Headquarters-Buildi.jpg?width=250&height=187 This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Evercore ISI Group analyst Amit Daryanani upgraded NetApp Inc (NASDAQ: NTAP) from In-Line to Outperform, raising the price target from $210 to $300, while the stock closed at $228.45 on Tuesday. Other notable upgrades include Humana Inc, Corteva Inc, Afya Ltd, and XPO Inc, with respective price target increases and adjustments. Humana's target rose from $300 to $460, Corteva's from Sector Weight to Overweight with a $17 target, Afya's target decreased from $21 to $19, and XPO's target increased from $220 to $224. https://openbell.ai/news/ETHU:1791376741201 2026-10-07T12:39:01.201Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/07/Sec-Securities-And-Exchange-Commission-I.jpg?width=250&height=187 Bitcoin, Ether, Oil, Gold: Volatility Shares Cracks the SEC Code to Bring 3x ETFs Back The SEC has approved a rule change for the Cboe BZX Exchange, allowing Volatility Shares to launch six triple-leveraged exchange-traded products (ETPs), including 3x Bitcoin and Ether ETFs. This approval is significant as it comes less than a year after the SEC expressed concerns about highly leveraged ETFs. The new products will be structured as commodity-based trust shares, enabling them to bypass certain regulatory restrictions that apply to conventional ETFs. The specific trading start date for these products has not been disclosed. https://openbell.ai/news/ABBV:1791376738544 2026-10-07T12:38:58.544Z daily 0.9 https://cdn.brandfetch.io/ABBV/w/400/h/400?c=1idopYfmtR7ZKg8QMud AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer AbbVie (NYSE: ABBV) has received two Breakthrough Therapy Designations from the U.S. FDA for its drug telisotuzumab adizutecan (Temab-A; ABBV-400) targeting colorectal cancer and non-small cell lung cancer. This designation is intended to expedite the development and review of therapies that show substantial improvement over existing treatments. https://openbell.ai/news/LTRN:1791376725707 2026-10-07T12:38:45.707Z daily 0.9 https://cdn.brandfetch.io/LTRN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lantern Pharma Announces Taiwan Approvals To Open Next Stage Of Phase 2 LP-300 Trial In Never-Smoker Lung Cancer openbell Financial News https://openbell.ai/news/XRAY:1791376698123 2026-10-07T12:38:18.123Z daily 0.9 https://cdn.brandfetch.io/XRAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Dentsply Sirona Unit Wellspect HealthCare Announces That Its Surity Urinary Management Portfolio May Be Covered By Traditional Medicare For Eligible Beneficiaries When Medically Necessary Wellspect HealthCare, a unit of Dentsply Sirona, announced that its Surity Urinary Management portfolio may now be covered by traditional Medicare for eligible beneficiaries when medically necessary. This development aims to enhance access to non-invasive urinary incontinence management solutions for over 13 million affected individuals in the U.S. The Surity portfolio, which includes Female and Male External Catheters and the Urinary Management System, was fully launched on August 18, 2026, and has gained significant online attention since its introduction. https://openbell.ai/news/HALO:1791376692572 2026-10-07T12:38:12.572Z daily 0.9 https://cdn.brandfetch.io/HALO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Halozyme Says Dutch Court Upholds Its Patent, Bars Merck From Making And Selling Keytruda SC In Multiple European Markets openbell Financial News https://openbell.ai/news/DXCM:1791376657808 2026-10-07T12:37:37.808Z daily 0.9 https://cdn.brandfetch.io/DXCM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115 Barclays analyst Christopher Pasquale has initiated coverage on DexCom (NASDAQ: DXCM) with an Overweight rating. The firm has set a price target of $115 for the company's stock. https://openbell.ai/news/IFF:1791376655360 2026-10-07T12:37:35.360Z daily 0.9 https://cdn.brandfetch.io/IFF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Argus Research Maintains Buy on Intl Flavors & Fragrances, Raises Price Target to $95 Argus Research analyst Alexandra Yates has maintained a 'Buy' rating on International Flavors & Fragrances (NYSE: IFF) and raised the price target from $85 to $95. This adjustment reflects a positive outlook for the company's stock performance. https://openbell.ai/news/ABT:1791376651513 2026-10-07T12:37:31.513Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/07/Abbott-Laboratories.jpg?width=250&height=187 This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Barclays analyst Matt Miksic initiated coverage on Abbott Laboratories (NYSE: ABT) with an Overweight rating and set a price target of $120. Abbott's shares closed at $98.16 on Tuesday, indicating potential upside based on the new target. This initiation is part of a broader trend of analysts adjusting their ratings on various companies, including Honeywell Aerospace and M&T Bank Corporation. https://openbell.ai/news/TRT:1791376641777 2026-10-07T12:37:21.777Z daily 0.9 https://cdn.brandfetch.io/TRT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trio-Tech International Receives New Three-Year, ~$4.45M Contract To Offer Burn-In Testing Equipment, Technical And Maintenance Support To Undisclosed European Automotive Semiconductor Customer Trio-Tech International (NASDAQ: TRT) has secured a new three-year contract worth approximately $4.45 million. The contract involves providing burn-in testing equipment and ongoing technical and maintenance support to an undisclosed European automotive semiconductor customer. https://openbell.ai/news/CHAR:1791376630044 2026-10-07T12:37:10.044Z daily 0.9 https://cdn.brandfetch.io/CHAR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Charlton Aria Announces $80M Pre-Money Deal To Combine With Korean Quantum Computing Firm KQC; Expects H1 2027 Close, Subject To Deadline Extension openbell Financial News https://openbell.ai/news/WGS:1791376574961 2026-10-07T12:36:14.961Z daily 0.9 https://cdn.brandfetch.io/WGS/w/400/h/400?c=1idopYfmtR7ZKg8QMud GeneDx To Present New Results At International Consortium On Newborn Sequencing For Its Genomic Newborn Screening GeneDx (Nasdaq: WGS) will present new findings at the International Consortium on Newborn Sequencing (ICoNS) on October 7-8 in Boston. The presentation will highlight advancements in making genomic newborn screening (gNBS) more scalable and accessible in proactive healthcare. https://openbell.ai/news/TWAV:1791376564867 2026-10-07T12:36:04.867Z daily 0.9 https://cdn.brandfetch.io/TWAV/w/400/h/400?c=1idopYfmtR7ZKg8QMud TaoWeave Says Investee Manako Labs Goes Live Commercially At 124 Avia Fuel Stations In France openbell Financial News https://openbell.ai/news/FBLG:1791376557865 2026-10-07T12:35:57.865Z daily 0.9 https://cdn.brandfetch.io/FBLG/w/400/h/400?c=1idopYfmtR7ZKg8QMud FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The Body FibroBiologics has filed a U.S. patent application for a novel cell-based technology aimed at continuously producing therapeutic peptides such as GLP-1, GIP, and GLP-2 within the body. This approach could potentially eliminate the need for regular injections or pills by administering engineered cells that act as peptide factories. The technology is designed to address various medical conditions, including diabetes, gastrointestinal diseases, and cancer, and includes features for safety and dosage control. The patent application emphasizes a platform capable of producing multiple therapeutic peptides simultaneously. https://openbell.ai/news/QTI:1791376545042 2026-10-07T12:35:45.042Z daily 0.9 https://cdn.brandfetch.io/QTI/w/400/h/400?c=1idopYfmtR7ZKg8QMud QT Imaging Says Distribution Partner NXC Imaging Signs National Group Purchasing Agreement With Premier For Breast Acoustic CT Scanner openbell Financial News https://openbell.ai/news/RNXT:1791376521872 2026-10-07T12:35:21.872Z daily 0.9 https://cdn.brandfetch.io/RNXT/w/400/h/400?c=1idopYfmtR7ZKg8QMud RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study RenovoRx, Inc. (NASDAQ: RNXT) has announced the enrollment of its first participant in the PRISM-TAMP trial, which focuses on PDAC regression and intraoperative surgical margins with neoadjuvant TAMP treatment. The trial is investigator-initiated and sponsored by the University of Vermont, with a second patient also moving toward treatment shortly after the trial's commencement. https://openbell.ai/news/ONDS:1791376474267 2026-10-07T12:34:34.267Z daily 0.9 https://cdn.brandfetch.io/ONDS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ondas Receives Over $165M Orders During Second Half Of August Through Oct. 1 Ondas Inc. (NASDAQ: ONDS) announced that it received over $165 million in orders from the second half of August through October 1st. This adds to approximately $105 million in orders secured earlier in the third quarter, bringing the total orders since June 30 to over $270 million. The increase in orders expands the Company's backlog and enhances revenue visibility into 2027. https://openbell.ai/news/BGLC:1791376472813 2026-10-07T12:34:32.813Z daily 0.9 https://cdn.brandfetch.io/BGLC/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioNexus Gene Lab Announces $3.5M All-Stock Deal For Exclusive 10-Year Malaysian Healthcare License To Ruanyun Edai's CogniAI Platform openbell Financial News https://openbell.ai/news/MIMI:1791376428987 2026-10-07T12:33:48.987Z daily 0.9 https://cdn.brandfetch.io/MIMI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mint's Axonex Robotics Announces About €450K Initial Order Under Two-Year Robot Kit Supply Contract With Centridex, Potential Value About €3M openbell Financial News https://openbell.ai/news/FEAM:1791376417724 2026-10-07T12:33:37.724Z daily 0.9 https://cdn.brandfetch.io/FEAM/w/400/h/400?c=1idopYfmtR7ZKg8QMud 5E Advanced Materials Announces Searles Valley Minerals Assets Takeover Provides ~257 Workforce, Three Processing Sites, Water Utility, 54 Megawatts Of On-Site Cogeneration Capacity 5E Advanced Materials, Inc. (NASDAQ: FEAM) has announced the acquisition of Searles Valley Minerals assets, marking its transition from a development stage company to an operator in the industrial and critical minerals sector. The acquisition includes approximately 257 employees, three processing sites, a water utility, and 54 megawatts of on-site cogeneration capacity. The company expects to achieve approximately $40 million in steady-state annual Adjusted EBITDA under its base plan. https://openbell.ai/news/AVX:1791376385743 2026-10-07T12:33:05.743Z daily 0.9 https://cdn.brandfetch.io/AVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud AVAX One Says It Reduced Debt By Over $14.9M In Q3, Cutting Convertible Debt To About $970K openbell Financial News https://openbell.ai/news/RARE:1791376319542 2026-10-07T12:31:59.542Z daily 0.9 https://cdn.brandfetch.io/RARE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has finalized a $210 million deal to sell a Rare Pediatric Disease Priority Review Voucher (PRV). The voucher was awarded following the FDA approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), the first treatment targeting the underlying cause of glycogen storage disease type Ia (GSDIa). https://openbell.ai/news/PPCB:1791376307515 2026-10-07T12:31:47.515Z daily 0.9 https://cdn.brandfetch.io/PPCB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Propanc Biopharma Says PRP Shows Over 90% Tumor Growth Inhibition In Animal Models Of Pancreatic Cancer openbell Financial News https://openbell.ai/news/PGNY:1791376276242 2026-10-07T12:31:16.242Z daily 0.9 https://cdn.brandfetch.io/PGNY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Progyny Expects 1.2 Million New Covered Lives From First-Half 2027 Launches, Including Anticipated Remaining Decisions openbell Financial News https://openbell.ai/news/XPO:1791376215384 2026-10-07T12:30:15.384Z daily 0.9 https://cdn.brandfetch.io/XPO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Citigroup Upgrades XPO to Buy, Raises Price Target to $224 Citigroup analyst Ariel Rosa has upgraded XPO (NYSE: XPO) from Neutral to Buy and increased the price target from $220 to $224. This change reflects a positive outlook on the company's performance. https://openbell.ai/news/NOW:1791376180388 2026-10-07T12:29:40.388Z daily 0.9 https://cdn.brandfetch.io/NOW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Argus Research Maintains Buy on ServiceNow, Raises Price Target to $170 Argus Research analyst Joseph Bonner has maintained a 'Buy' rating on ServiceNow (NYSE: NOW) and increased the price target from $134 to $170. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/TDOC:1791375923021 2026-10-07T12:25:23.021Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/07/Doctor-Looking-At-Human-Teeth-X-ray.jpg?width=250&height=187 Teladoc Turns Smartphone Cameras Into AI-Powered Vital Sign Monitors Teladoc Health, Inc. (NYSE: TDOC) has introduced two AI-powered tools, SoloVitals and SoloScribe, to enhance its Solo platform for virtual care. SoloVitals enables contactless monitoring of heart and respiration rates using smartphone cameras, while SoloScribe automates clinical note-taking during virtual appointments. The Solo platform is currently utilized in over 15,000 care locations globally, and Teladoc anticipates a broader release of SoloVitals in December 2026. As of the latest trading, Teladoc's stock is priced at $5.79, showing a modest increase despite a 31.06% decline over the past year. https://openbell.ai/news/CHAR:1791375900429 2026-10-07T12:25:00.429Z daily 0.9 https://cdn.brandfetch.io/CHAR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending openbell Financial News https://openbell.ai/news/MRVL:1791375765951 2026-10-07T12:22:45.951Z daily 0.9 https://cdn.brandfetch.io/MRVL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Susquehanna Maintains Positive on Marvell Technology, Raises Price Target to $340 Susquehanna analyst Christopher Rolland has maintained a Positive rating on Marvell Technology (NASDAQ: MRVL) and increased the price target from $265 to $340. https://openbell.ai/news/AAPL:1791375661123 2026-10-07T12:21:01.123Z daily 0.9 https://cdn.brandfetch.io/AAPL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported Oct. 6: 'Apple to Launch Doorbell, Lock, Thermostat Developed With LG' - Bloomberg Apple is set to launch a new line of smart home products, including a doorbell, lock, and thermostat, developed in collaboration with LG. This move is part of Apple's strategy to expand its presence in the smart home market. The announcement comes as Apple continues to innovate and diversify its product offerings. https://openbell.ai/news/ICU:1791375501321 2026-10-07T12:18:21.321Z daily 0.9 https://cdn.brandfetch.io/ICU/w/400/h/400?c=1idopYfmtR7ZKg8QMud SeaStar Medical Receives FDA's Medical Breakthrough Device Designation For Its Selective Cytopheretic Device Therapy To Treat Hyperinflammation SeaStar Medical Holding Corporation (NASDAQ: ICU) has received FDA's Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy aimed at treating hyperinflammation in adult patients with sepsis. This designation facilitates accelerated development and review for FDA approval, marking the seventh such designation for the SCD therapy across various indications. https://openbell.ai/news/ICU:1791375452056 2026-10-07T12:17:32.056Z daily 0.9 https://cdn.brandfetch.io/ICU/w/400/h/400?c=1idopYfmtR7ZKg8QMud SeaStar Medical Receives FDA's Medical Breakthrough Device Designation For Its Selective Cytopheretic Device Therapy To Treat Hyperinflammation SeaStar Medical Holding Corporation (NASDAQ: ICU) has received Breakthrough Device Designation from the FDA for its Selective Cytopheretic Device (SCD) therapy, aimed at treating hyperinflammation in adult patients with sepsis. This designation facilitates accelerated development and review for FDA approval of the device, which is intended for life-threatening conditions. This is the seventh Breakthrough Device Designation granted for the SCD therapy across various indications. https://openbell.ai/news/FBLG:1791375354236 2026-10-07T12:15:54.236Z daily 0.9 https://cdn.brandfetch.io/FBLG/w/400/h/400?c=1idopYfmtR7ZKg8QMud EXCLUSIVE: FibroBiologics Files US Patent Application For New Technology Designed To Produce GLP-1 And Other Therapeutic Peptides Inside The Body, As An Alternative To Repeated Injections openbell Financial News https://openbell.ai/news/ABEV:1791375317037 2026-10-07T12:15:17.037Z daily 0.9 https://cdn.brandfetch.io/ABEV/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Downgrades Ambev to Underperform, Maintains Price Target to $3.3 B of A Securities analyst Isabella Simonato has downgraded Ambev (NYSE: ABEV) from Neutral to Underperform. The price target for the stock remains unchanged at $3.3. https://openbell.ai/news/FBLG:1791375306354 2026-10-07T12:15:06.354Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/07/Weight-loss.jpg?width=250&height=187 EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections FibroBiologics Inc. (NASDAQ: FBLG) has filed a U.S. patent application for a cell-based platform that aims to produce therapeutic peptides continuously within the human body, potentially serving as a long-term alternative to traditional GLP-1 injections for weight-loss and diabetes treatments. The technology targets various conditions beyond metabolic disorders, including gastrointestinal diseases and cancer, and features immune-evasive modifications and safety switches. During premarket trading on Wednesday, FibroBiologics shares were down 1.28% at $1.11. https://openbell.ai/news/SRXH:1791375108507 2026-10-07T12:11:48.507Z daily 0.9 https://cdn.brandfetch.io/SRXH/w/400/h/400?c=1idopYfmtR7ZKg8QMud SRX Global Inks Stock Purchase Agreement With Cero Therapeutics; To Acquire All Outstanding Stock Of Cero Therapeutics SRX Global has entered into a stock purchase agreement to acquire all outstanding shares of Cero Therapeutics. This strategic move aims to enhance SRX Global's portfolio and market presence. The financial terms of the acquisition were not disclosed in the announcement. https://openbell.ai/news/LABT:1791375093844 2026-10-07T12:11:33.844Z daily 0.9 https://cdn.brandfetch.io/LABT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds. openbell Financial News